Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235963 · ClinicalTrials.gov registry record · Phase 1
A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
A Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT00235963: Completed Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm, sponsored by Brigham and Women's Hospital.
NCT00235963 is a Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 104 participants, below the 3,583-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00235963, a Phase 1 study of Subarachnoid Hemorrhage and Delayed Vasospasm, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.
Conditions Studied
Interventions
- DRUG Simvastatin
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2002-12 |
| Est. Completion | 2006-02 |
| Phase | Phase 1 |
What the finished NCT00235963 record still lists
NCT00235963 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 3,583-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin is the first listed.
NCT00235963 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00235963 about?
NCT00235963 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm". To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.
What is the current status of trial NCT00235963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2002-12. Estimated completion is 2006-02.
What conditions does trial NCT00235963 study?
This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Delayed Vasospasm.
What interventions are being tested in trial NCT00235963?
The interventions under investigation include: Simvastatin (DRUG).
Who is sponsoring clinical trial NCT00235963?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00235963 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subarachnoid Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00235963's enrollment target sits among peer trials
104 10th of 21 higher than 12 of 21 other Subarachnoid Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Subarachnoid Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury
RECRUITING · Phase 1
-
Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?
RECRUITING · Phase 1
-
Remote Ischemic Preconditioning in Subarachnoid Hemorrhage
COMPLETED · Phase 1
-
Subarachnoid Hemorrhage Recovery And Galantamine
COMPLETED · Phase 1
-
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia